BOSTON, MA--(Marketwire - March 11, 2008) - The number of monoclonal antibody products -- known as mAbs -- entering clinical study nearly tripled in the last decade and now require 7.6 years on average to complete the clinical development process and receive marketing approval, according to a new study completed by the Tufts Center for the Study of Drug Development.
